actelion Resources | BNET
On The Insider: Amy Winehouse Has Brain Damage?

Resources

10 Resources for

actelion

  • Subscribe to this listing via:
  • RSS
  • Email
Medarex Inc. (Active Pharmaceutical Ingredient Watch).(rumored to be potential bidder with Actelion Ltd. to buy Oxford Glysosciences PLC)(Brief Article)
MEDAREX Inc. and ACTELION Ltd. are rumored to be potential bidders to acquire Oxford Glycosciences PLC OGS, according to West LB Panmure ... MEDAREX Inc. and ACTELION Ltd. are rumored to be potential bidders to acquire Oxford Glycosciences PLC OGS, according to West LB...
Research articles 2003-03-03
Actelion Receives Frost & Sullivan 2007 North American Pulmonary Arterial Hypertension Market Leadership Award
PALO ALTO, Calif. -- Frost & Sullivan today announced that it has awarded the 2007 North American Pulmonary Arterial Hypertension PAH Market Leadership of the Year Award to Actelion Pharmaceuticals US, Inc. According to Frost & Sullivan's research, Actelion is the key leader in the U.S. PAH market. Actelion's product...
Tags: Frost & Sullivan, leadership
Research articles 2007-09-20
Genentech Inc.
GENENTECH Inc. and Actelion Ltd. have signed a development and copromotion licensing agreement for tezosentan, and endothelin receptor antagonist used in treating acute heart failure. Genentech ... GENENTECH Inc. and Actelion Ltd. have signed a development and copromotion licensing agreement for tezosentan, and endothelin...
Tags: Genentech Inc.
Research articles 2000-02-28
Actelion To Present At the Bear Stearns 15th Annual Healthcare Conference
Business Editors
Tags: Bear Stearns & Co. Inc., health care
Research articles 2002-09-11
Actelion and Genentech Sign Licensing Agreement For Tracleer 'Bosentan' In The U.S
Business Editors/High-Tech Writers
Tags: Genentech Inc., licensing agreement
Research articles 2000-12-13
Actelion and Genentech Announce First Endothelin Receptor Antagonist Shows Positive Preliminary Results for Acute Heart Failure
Business Editors/Medical Writers
Tags: Genentech Inc.
Research articles 2001-03-20
Genentech and Actelion Announce March 20 Webcast Discussion of Veletri — Tezosentan — RITZ-2 Trial Results
Business Editors/Medical Writers
Tags: Genentech Inc., Webcast
Research articles 2001-03-16
CSFB improves Sfr125m Actelion convertible terms.
Byline: Shanny Basar Byline: Shanny Basar
Tags: Credit Suisse First Boston
Research articles 2003-10-01
Biotechnology Pioneer Jean-Paul Clozel Named Ernst & Young World Entrepreneur Of The Year 2008
MONTE CARLO, Monaco -- Dr. Jean-Paul Clozel, founder of Switzerland's Actelion Pharmaceuticals Ltd., a pioneering biotechnology company, was last night named the Ernst & Young World Entrepreneur Of The Year 2008 at an awards ceremony held in Monte Carlo's Salle des Etoiles. Clozel was picked from among entrepreneurs representing more...
Tags: biotechnology, Ernst & Young LLP
Research articles 2008-06-01
United Therapeutics' 10-Q Suggests Dangerous Over-Reliance on Its Top Product
United Therapeutics Corp. derives almost all of its commercial sales from its top product Remodulin, a treatment for pulmonary arterial hypertension. In 2009, however, the biotechnology company could be drifting into troubled waters. For the six-months ended June 30, Remodulin accounted for approximately 95 percent of the $130.6 million in...
Tags: FDA, Patient, Therapy, Remodulin, Federal Government, Government, David Phillips
Blog posts 2008-08-27
  • << Previous
  • page 1 of 1
  • Next >>
advertisement
advertisement